Drug Trial Radar · NCT00277602
Riluzole in Huntington's Disease
Last checked: Nov 20, 2026Latest source record: Feb 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
537
Actual
Start
Nov 1999
Primary completion
Jul 2004
Study completion Jul 2004
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: * The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating Scale (UHDRS) as well as (3) the increase of a combined score of these. Secondary objectives: Secondary objectives are to assess * changes in the other UHDRS subscales * the number of patients who need antichoreic treatment and the time until this treatment has to be initiated * the safety/tolerability of riluzole in Huntington patients
Conditions
- Huntington Disease
Interventions
RiluzoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- UHDRS-motor score, TFC
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.